[HTML][HTML] Ipilimumab and pembrolizumab mixed response in a 41-year-old patient with SMARCA4-deficient thoracic sarcoma: an interdisciplinary case study
N Anžič, F Krasniqi, AL Eberhardt, A Tzankov… - Case Reports in …, 2021 - karger.com
SMARCA4-deficient thoracic sarcoma is a newly described entity of thoracic sarcomas with
a poor prognosis, defined by poorly differentiated epithelioid to rhabdoid histomorphology …
a poor prognosis, defined by poorly differentiated epithelioid to rhabdoid histomorphology …
Case report: A rapid response to immunotherapy in a thoracic SMARCA4-deficient undifferentiated tumor with respiratory failure
L Shi, L Lin, Y Ding, Y Zeng, X Chen - Frontiers in Oncology, 2022 - frontiersin.org
Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is an extremely rare
and poor-prognosis malignancy, which has recently been noted as a subtype of lung tumors …
and poor-prognosis malignancy, which has recently been noted as a subtype of lung tumors …
OPEN ACCESS EDITED BY
K Fujita, S Rao, M Migliore, X Jiang… - Case Reports in …, 2024 - books.google.com
As the molecular biology of lung cancer advances, immunotherapy and targeted therapy
have become standard treatment protocols for advanced lung cancer in clinical practices …
have become standard treatment protocols for advanced lung cancer in clinical practices …